Loading stock data…
Bicycle Therapeutics plc (BCYC)
$4.18-0.12 (-2.79%)
Market ClosedLast close Sep 8
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BCYC in the Healthcare sector is trading at $4.18. Wall Street consensus targets $9.50 (6 analysts), implying a +127.3% move over the next 12 months. The stock is currently near its 52-week low of $3.75, remaining 19.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +127.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $629,000↓ | $887,000↓ | $47.95M↑ | $11.73M↑ | $2.92M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$54.63M↑ | -$65.59M↓ | -$24.66M↑ | -$65.71M↑ | -$87.35M |
| Net Income | -$50.33M↑ | -$60.83M↓ | -$20.15M↑ | -$59.10M↑ | -$78.95M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenecti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.32%
Volume
Today's trading volume
262,704
Recent News
European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending higher late Wednesd
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
European equities traded in the US as American depositary receipts were marginally higher late Frida
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking lower late Wednesda
European Equities Traded in the US as American Depositary Receipts Track Higher in Friday Trading
European equities traded in the US as American depositary receipts were trending higher late Friday
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking higher late Wednesd